

# Cencora ThinkLive Cell and Gene Therapy Summit 2025

Building sustainable solutions for tomorrow's therapies

### Day 1 - Tuesday, May 20, 2025

#### 11:00 - 11:10 am ET

#### Welcome and introduction

 John Arena, President, Global Pharma Services, Cencora

### 11:10 - 11:55 am ET

### Panel, Q&A

### Maximizing impact: Strategies for building robust patient support programs

- **Discover strategies** to align drug developers' patient services with the real needs of patients
- Hear insights from patient advocates on the importance of incorporating feedback into support programs
- **Engage with** patient support field leaders in a live Q&A session

### **Speakers:**

Melissa Mulchahey, Cencora, Moderator; Dawn Ratfelders, Neurotech; Elizabeth Turcotte, Pierre Fabre Pharmaceuticals; George Eastwood, Emily Whitehead Foundation; Zack Bridges, Cencora

### 11:55 am – 12:10 pm ET Case study

### The journey of resilience to pioneering a new therapy

- Learn how a pharma company navigated the complexities of patient needs and regulatory challenges in the pursuit of bringing a novel gene therapy to market
- Discover how our partnership united diverse services to create a seamless CGT solution amidst significant hurdles

#### **Speakers:**

Nancy Hoak, Cencora, Moderator; Jen McDonough, Krystal Biotech

### 12:10 – 12:40 pm ET Panel

### The power of integrated distribution strategies for cell and gene therapies

- **Learn how** integrated solutions improved patient and market access
- **Discuss planning** for a scalable distribution strategy to enable expansion into future markets
- Explore the advantages of partnerships that enhancepatient support and streamline therapy distribution

#### **Speakers:**

Melissa Lattanzi, Cencora, Moderator; Darin DeCarlo, Orsini; Guillaume Nebout, Cencora; Morgan Marr, Ferring Pharmaceuticals

### 12:40 - 1:25 pm ET

**Panel** 

## Designing for success: A health systems perspective on tailoring your program for the commercial landscape

- Examine the key concerns health systems face with the influx of CGTs and strategies to manage these hurdles effectively
- Discover how integrated programs can alleviate health systems' apprehensions and streamline the adoption of new therapies
- Learn best practices for drug manufacturers to collaborate with health systems, enhancing patient access and optimizing therapy implementation

### **Speakers:**

Ben Shaffer,
Cencora, Moderator;
Ashley Dalton,
UC San Diego;
Donn Davis,
Moffit Cancer Center;
Justin Konkol, Froedtert &
Medical College of Wisconsin;
Stephanie Wirkes, Bayer

### 1:25 - 1:45 pm ET

Fireside chat

### Engaging stakeholders to showcase value and drive impact

- **Discuss effective strategies** for articulating the value of CGTs to key stakeholders and addressing existing gaps in the narrative
- Shaping the future: Learn how ARM is actively working to influence the conversation around high-value drugs and why stakeholder engagement is crucial for the success of CGTs in today's market

#### **Speakers:**

Louis Cicchini, Cencora, Moderator; Rita Johnson-Greene, Alliance for Regenerative Medicine

### Day 2 – Wednesday, May 21, 2025

#### 11:00 - 11:15 am ET

Welcome and insights

- Kevin Chinn VP and Head of Cell and Gene Service Line, Cencora
- Mark Kelley Senior Director, CGT Enterprise Partnerships, Cencora

### 11:15 - 11:35 am ET

Learning Session, Q&A

### The first 5 months: Practical implications of the HTA/JCA

- Gain practical insights into the real-world implications of the HTA/JCA's full implementation, including successes and challenges faced
- Engage our expert as she shares in a live Q&A

### **Speakers:**

**Ann-Sophie Kuschel,** Vintura, a Cencora Company

### 11:35 - 12:20 pm ET

**Panel** 

### Navigating special regulatory pathways for drug development success

- Explore the latest special regulatory programs from the FDA and EMA that are designed to accelerate the development of advanced therapies
- Learn best practices for effectively engaging with regulatory agencies to leverage these powerful programs and maximize their benefits for drug development

### **Speakers:**

Herbert Altmann,
Cencora, Moderator;
Arvind Natarajan,
Iovance Biotherapeutics;
Christian Schneider,
Cencora PharmaLex;
Malou Gemeniano,
Iovance Biotherapeutics;
Monica King, Cook Myosite;
Nathalie Boeglin,
Orchard Therapeutics

### 12:20 - 12:30 am ET

#### Learning session

### Current executive landscape and impacts to CGT development

### Hear from Cencora's U.S. Policy team on how the current U.S. administration's actions and orders impact the CGT market

### **Speakers:**

Whitley Quan, Cencora

### 12:30 - 1:00 pm ET

#### Fireside chat

### FDA: Embracing flexibility at the agency for advancing innovative therapies

- Reflect on key achievements at the FDA that have advanced regulatory frameworks and fostered innovation in regenerative medicine
- Discuss anticipated shifts in CBER's regulatory focus under new leadership, strategies for stakeholder engagement, and opportunities for collaboration to enhance the approval process

#### **Speakers:**

Louis Cicchini, Cencora, Moderator; Celia Witten, Eliquent Life Sciences

### 1:00 - 1:25 pm ET Panel

### Strategic logistics: Crafting scalable solutions for maximum reach and success

- Discover the importance of designing your CGT program with scalability in mind, ensuring logistics support both clinical and commercial needs from the outset
- Feasibility in focus: Learn how to develop a manufacturing and logistics strategy that is not only feasible for clinical research but also capable of scaling effectively for larger commercial operations
- Understand how integrating market access strategies early in the logistics planning process can enhance overall success and patient reach for CGTs

### **Speakers:**

Krystal Haynes, Cencora, Moderator; David Sokoloff, Precigen; Eric Schier, Cencora World Courier

### 1:25 - 1:50 pm ET Fireside chat

#### Closing and thoughts on tomorrow's therapies

 Future perspectives: Engage in a fireside chat with advocacy leader ARM as we recap recent highlights in the industry and discuss the exciting prospects and advancements anticipated in CGT

#### **Speakers:**

Kevin Chinn, Cencora, Moderator; Tim Hunt, Alliance for Regenerative Medicine

<u>Click here</u> to learn more about Cencora's solutions for Cell and Gene Therapies and register for this event

